[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-456216-105":59,"doc-detail-456216-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","vascular-pathology-drives-the-association-of-plasma-gfap-with-gray-matter-atrophy-and-cognitive-decline-in-amyloid-negative-individuals","Vascular pathology drives the association of plasma GFAP with gray matter atrophy and cognitive decline in amyloid-negative individuals","","Background: Amyloid (Aβ) pathology strengthens the relationship between GFAP, a marker of reactive astrogliosis, and neurodegeneration, but GFAP’s link to neurodegeneration without Aβ remains unresolved. Preclinical work suggests vascular pathology can activate glial cells and trigger harmful effects. Objective: test whether vascular pathology similarly potentiates plasma GFAP effects on neurodegeneration and cognitive decline in Aβ-negative individuals. Study: 324 participants stratified by WMH status (Fazekas 1 vs 2–3) using imaging and biomarker measures, analyzed with ANCOVA and regression.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/vascular-pathology-drives-the-association-of-plasma-gfap-with-gray-matter-atrophy-and-cognitive-decline-in-amyloid-negative-individuals/456216/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/vascular-pathology-drives-the-association-of-plasma-gfap-with-gray-matter-atrophy-and-cognitive-decline-in-amyloid-negative-individuals/456216.png","ImageObject",300,407,{"name":92,"@type":93},"Jasmine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-07","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What hypothesis did the study test about vascular pathology and plasma GFAP?","Question",{"text":112,"@type":113},"It tested whether, like Aβ pathology, vascular pathology potentiates the effects of plasma GFAP on neurodegeneration and cognitive decline in Aβ-negative individuals.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were participants grouped in the analysis?",{"text":117,"@type":113},"The study included 324 cognitively impaired, Aβ-negative participants and divided them by WMH status into Fazekas 1 (Fz1) and Fazekas 2–3 (Fz2-3) groups.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings in the Fazekas 2–3 group?",{"text":121,"@type":113},"Fz2-3 showed more hippocampal atrophy and higher plasma NfL levels, with no plasma GFAP change overall reported in the result section; hippocampal atrophy and cognitive decline were associated with plasma GFAP.",{"name":123,"@type":110,"acceptedAnswer":124},"Which peripheral vascular risk factors contributed most to the associations?",{"text":125,"@type":113},"Among evaluated PVPs, hypertension (HTN) and diabetes (DBT) showed stronger effects on the association of plasma GFAP with hippocampal atrophy and cognitive decline.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},456216,1790813714,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":81,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":39},2336478487870,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","DOI: 10. 1002/alz70856_105134  \nBIOMARKERS  \nPODIUM PRESENTATION  \nNEUROIMAGING  \nVascular pathology drives the association of plasma GFAP with gray matter atrophy and cognitive decline in amyloid-negative individuals  \nMarkley Silva Oliveira Jr.1  MatheusScarpatto Rodrigues1  Guilherme Povala 1  MarinaScop Medeiros 1  João Pedro Ferrari-Souza2  Firoza Z Lussier 1   \nPamela C. L. Ferreira 1  Guilherme Bauer-Negrini 1  Livia Amaral 1  Andreia Rocha 1 Sarah Abbas 1  Hussein Zalzale 1  Carolina Soares 1  Pampa Saha 1   \nDana L Tudorascu 1  Cynthia Felix 1  Rayan Mroué 1  Hyun Woong Roh3  Eduardo R. Zimmer4, 5, 6, 7, 8, 9, 10  Thomas K Karikari 1  Chang Hyung Hong3   \nSang Joon Son3  Bruna Bellaver 1  Tharick A Pascoal 1  \n1 University of Pittsburgh, Pittsburgh, PA, USA  \n2 Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil  \n3Ajou University School of Medicine, Suwon, Gyeonggido, Korea, Republic of (South)  \n4 Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil  \n5 McGill Centre for Studies inAgin, Montreal, QC, Canada  \n6 Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil  \n7 Brain Institute of Rio Grande Do Sul, PUCRS, Porto Alegre, RS, Brazil  \n8 Brain Institute of Rio Grande do Sul, Porto Alegre, Brazil  \n9 Brain Institute of Rio Grande do Sul (InsCer), PUCRS, Porto Alegre, Rio Grande do Sul, Brazil  \n10 McGill Centre for Studies in Aging, Montreal, QC, Canada  \nCorrespondence  \nMatheus Scarpatto Rodrigues, University of Pittsburgh, Pittsburgh, PA, USA. [Email:](Email: msr104@pitt.edu)[ msr104@pitt.edu](Email: msr104@pitt.edu)  \nAbstract  \nBackground: Amyloid (Aβ) pathology potentiates the association between GFAP, a biomarker for reactive astrogliosis, and neurodegeneration, while it remains unclear whether GFAP is associated with neurodegeneration without Aβ abnormalities. Preclinical studies suggest vascular pathology may activate glial cells, triggering deleterious effects. Here, we tested the hypothesis that, similar to Aβ pathology, vascular pathology may also potentiate the effects of plasma GFAP on neurodegeneration and cognitive decline inAβ-negative individuals.  \nMethod: We assessed 324 cognitively impaired (CDR \u003C 0) Aβ-negative (Centiloid \u003C 24) participants from a memory clinic cohort (BICWALZS), with available CDR global, MMSE, plasma GFAP, clinical assessment of peripheral vascular risk factors [PVPs: hypertension (HTN), diabetes (DBT), and dyslipidemia (DLP)], FLAIR and T1-based volumetrics. Participants were divided into two groups according to their WMH status: Fazekas 1 (Fz1; n = 203) and Fazekas 2-3 (Fz2-3; n = 121). Group differences were analyzed using ANCOVA. Associations were assessed using linear regressions, and the contribution of PVPs to the effects of biomarkers was accessed through multicollinearity analysis accounting for age, sex, and years of education.  \nResult: Individuals in the Fz2-3 group showed more hippocampal atrophy (Figure 1A, 1B; p = 0.0115), plasma NfL levels (1C; p = 0.0020), no changes in plasma GFAP  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Alzheimer’s Association. Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association.  \nAlzheimer’s Dement. 2025;21(Suppl. 2):e105134.  \n[https://doi.org/10.1002/alz70856_105134](https://doi.org/10.1002/alz70856_105134)  \nwi[leyonlinelibrary.com/journal/alz](leyonlinelibrary.com/journal/alz)  \n1of3  \nBIOMARKERS  \nlevels (Figure 1D) and lower MMSE score (Figure 1E). In the Fz2-3 group, hippocampal atrophy (Table 1; β: -0.179, p = 0.0440) and cognitive decline (Table 1; β: -0.194, p = 0.0390) was associated with plasma GFAP. No abnormalities or associations between biomarkers were found in the Fz1 group. Among the PVPs evaluated, HTNand DBT presented a stronger effect i","cbCaifDnA7B31GMV","https://ap.wps.com/l/cbCaifDnA7B31GMV","pdf",1482752,"English","# Abstract\n## Background\n## Method\n## Result\n## Conclusion","[{\"question\":\"What hypothesis did the study test about vascular pathology and plasma GFAP?\",\"answer\":\"It tested whether, like Aβ pathology, vascular pathology potentiates the effects of plasma GFAP on neurodegeneration and cognitive decline in Aβ-negative individuals.\"},{\"question\":\"How were participants grouped in the analysis?\",\"answer\":\"The study included 324 cognitively impaired, Aβ-negative participants and divided them by WMH status into Fazekas 1 (Fz1) and Fazekas 2–3 (Fz2-3) groups.\"},{\"question\":\"What were the key findings in the Fazekas 2–3 group?\",\"answer\":\"Fz2-3 showed more hippocampal atrophy and higher plasma NfL levels, with no plasma GFAP change overall reported in the result section; hippocampal atrophy and cognitive decline were associated with plasma GFAP.\"},{\"question\":\"Which peripheral vascular risk factors contributed most to the associations?\",\"answer\":\"Among evaluated PVPs, hypertension (HTN) and diabetes (DBT) showed stronger effects on the association of plasma GFAP with hippocampal atrophy and cognitive decline.\"}]","Vascular pathology drives the association of plasma GFAP with gray matter atrophy and cognitive decline in amyloid-negative individuals | PDF",1790745358]